ArticleJHEP reports : innovation in hepatology2021
A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients.
Article in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of a Diet Rich in Inulin-type Fructans Combined With Inulin Supplementation on Gut Microbiota Composition and Metabolic Parameters in Obese Patients
MYO-SLD : a Prospective Study to Determine the Phenotype of Muscle Fat Accumulation in a Cohort of Patients With SLD as to Confirm the Association Between Muscle Composition and Texture and the Phenotype of Liver Disease
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Effect of host and gut microbiota-altering interventions on sarcopenia or its defining parameters: a systematic review and meta-analysis of nutrition-based intervention studies.Aging clinical and experimental research · 2025Pooled it
- Review
- Article
- The liver-muscle axis in metabolic dysfunction-associated steatotic liver disease: a narrative review and conceptual framework for body-composition phenotyping.Frontiers in medicine · 2026Review
- Quality and Quantity? The Clinical Significance of Myosteatosis in Various Liver Diseases: A Narrative Review.Journal of clinical and translational hepatology · 2025Review
- Myosteatosis: Epidemiological Insights, Functional Decline, and Diagnostic Advances.Current obesity reports · 2025Review
- Skeletal muscle fatty deposition in young and middle-aged adults with metabolic dysfunction-associated fatty liver disease: a magnetic resonance proton density fat fraction study.Quantitative imaging in medicine and surgery · 2025Article
- Skeletal muscle and MASLD: Mechanistic and clinical insights.Hepatology communications · 2025Review
- Sugar-sweetened beverage consumption predicts metabolic associated fatty liver disease in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
- MAFLD as part of systemic metabolic dysregulation.Hepatology international · 2024Review
- Strength in quality: Myosteatosis as a predictor of survival in advanced hepatocellular carcinoma.United European gastroenterology journal · 2024Article
- Quantitative Assessment of Body Composition in Cirrhosis.Diagnostics (Basel, Switzerland) · 2024Review
- The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.BMC gastroenterology · 2024Article
- Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.European radiology · 2024Article
- Metabolic-associated fatty liver disease and sarcopenia: A double whammy.World journal of hepatology · 2024Review
- Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.JHEP reports : innovation in hepatology · 2024Review
- Combined impact of myosteatosis and liver steatosis on prognosis in stage I-III colorectal cancer patients.Journal of cachexia, sarcopenia and muscle · 2023Article
- Alcohol Consumption and Skeletal Muscle: What We Know and What We Would Like to Know.Calcified tissue international · 2023Article
- Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease.Gut and liver · 2023Article
- AI-based CT Body Composition Identifies Myosteatosis as Key Mortality Predictor in Asymptomatic Adults.Radiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsRetrospective cross-sectional studies linked sarcopenia and myosteatosis with metabolic dysfunction-associated fatty liver disease (MAFLD). Here, we wanted to clarify the dynamic relationship between sarcopenia, myosteatosis, and MAFLD.
methodsA cohort of 48 obese patients was randomised for a dietary intervention consisting of 16 g/day of inulin (prebiotic) or maltodextrin (placebo) supplementation. Before and after the intervention, we evaluated liver steatosis and stiffness with transient elastography (TE); we assessed skeletal muscle index (SMI) and skeletal muscle fat index (SMFI) (a surrogate for absolute fat content in muscle) using computed tomography (CT) and bioelectrical impedance analysis (BIA).
resultsAt baseline, sarcopenia was uncommon in patients with MAFLD (4/48, 8.3%). SMFI was higher in patients with high liver stiffness than in those with low liver stiffness (640.6 ± 114.3 cm
conclusionsMyosteatosis, but not sarcopenia, is strongly and independently associated with liver stiffness in obese patients with MAFLD. After intervention, patients in which the degree of myosteatosis decreased reduced their liver stiffness, irrespective of body weight loss or prebiotic treatment. The potential contribution of myosteatosis to liver disease progression should be investigated. CLINICAL TRIALS REGISTRATION NUMBER: NCT03852069. LAY SUMMARY: The fat content in skeletal muscles (or myosteatosis) is strongly associated with liver stiffness in obese patients with MAFLD. After a dietary intervention, patients in which the degree of myosteatosis decreased also reduced their liver stiffness. The potential contribution of myosteatosis to liver disease progression should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.